Postmenopausal osteoporosis is a highly prevalent condition associated with substantial morbidity and mortality, while current treatment with romosozumab, a monoclonal antibody that both stimulates bone formation and inhibits bone resorption, is limited by high cost, monthly clinic-administered injections, waning anabolic effects over time, and potential cardiovascular risks. To address these challenges, a clinical trial evaluated whether a shorter course of romosozumab could provide efficacy comparable to the standard treatment regimen in improving bone mineral density in patients with postmenopausal osteoporosis, involving 188 participants.
The study found that the mean 12-month increase in total hip bone mineral density (BMD) was 5.7% (SD 3.3) in the 3-month romosozumab group compared with 6.0% (SD 3.2) in the 12-month romosozumab group, with the between-group difference meeting the…
